RESEARCHER PROFILE

Gül Başaran

← Back to Acıbadem University

G

Acıbadem University

Breast Cancer Treatment StudiesBreast Lesions and CarcinomasHER2/EGFR in Cancer ResearchGastric Cancer Management and OutcomesAdvanced Breast Cancer Therapies

Gül Başaran works in Breast Cancer Treatment Studies, Breast Lesions and Carcinomas, HER2/EGFR in Cancer Research, Gastric Cancer Management and Outcomes, Advanced Breast Cancer Therapies. Recorded institutional associations include Acıbadem University.

175Publications
2,125Citations
19H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    2017 · 585 citations
  2. Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer

    2008 · 348 citations
  3. Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer

    2008 · 216 citations
  4. HPV DNA frequency and subset analysis in human breast cancer patients' normal and tumoral tissue samples.

    2006 · 97 citations
  5. Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

    2024 · 91 citations
  6. The association between individual attachment patterns, the perceived social support, and the psychological well‐being of Turkish informal caregivers

    2009 · 68 citations
  7. Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer

    2009 · 49 citations
  8. Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer

    2017 · 48 citations
  9. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: Findings from the EORTC 10001 randomized phase II trial

    2007 · 47 citations
  10. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials

    2015 · 45 citations
  11. Vascular Endothelial Growth Factor, Hypoxia-Inducible Factor 1 Alpha and CD34 Expressions in Early-Stage Gastric Tumors: Relationship with Pathological Factors and Prognostic Impact on Survival

    2007 · 40 citations
  12. A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)

    2015 · 36 citations
  13. De-Escalation of Nodal Surgery in Clinically Node-Positive Breast Cancer

    2025 · 30 citations
  14. Weight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey

    2010 · 29 citations
  15. Epithelioid hemangioendothelioma with multiple organ involvement

    2007 · 28 citations
  16. Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial

    2026 · 26 citations
  17. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

    2023 · 24 citations
  18. Clinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years?

    2010 · 21 citations
  19. Impact of body mass index on cancer development.

    2008 · 12 citations
  20. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes

    2018 · 12 citations
  21. Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak

    2020 · 12 citations
  22. Combined analysis of the MF18‐02/MF18‐03 NEOSENTITURK studies: ypN‐positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided

    2024 · 12 citations
  23. Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer

    2012 · 11 citations
  24. A case of Kikuchi-Fujimoto disease misdiagnosed as Hodgkin's lymphoma: the importance of second opinion.

    2009 · 10 citations
  25. Clinical Outcome of Turkish Metastatic Breast Cancer Patients with Currently Available Treatment Modalities - Single Center Experience

    2014 · 10 citations

← Return to the university profile